IP Library › Patent Application 16319147
Patent Application
App. No. 16/319,147

COMBINATION THERAPY USING A CD19-ADC AND RCHP

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/319,147
Abstract

This invention relates to treatment of Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Specifically, the disclosure provides a method of treating a subject having DLBCL or FL, the method comprising administering to the subject a drug combination consisting essentially of a CD19 antibody drug conjugate (CD19-ADC), and rituximab, cyclophosphamide, doxorubicin, and prednisone (RCHP).

Claims (24)

1 . A method of treating a subject having Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL), the method comprising administering to the subject a drug combination consisting essentially of a CD19 antibody drug conjugate (CD19-ADC) , and rituximab, cyclophosphamide, doxorubicin, and prednisone (RCHP).

2 . The method of claim 1 , wherein the CD19-ADC comprises a humanized hBU12 antibody conjugated to a maleimidocaproyl monomethyl auristatin F (mcMMAF) molecule.

3 . The method of claim 1 , wherein the CD19-ADC is SGN-CD19A.

4 . The method of claim 1 , wherein Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) in the subject has not been previously treated.

5 . The method of claim 1 , wherein the CD19-ADC is administered at a dosage between 0.5 and 6.0 mg/kg based on the weight of the subject.

6 . The method of claim 1 , wherein the CD19-ADC is administered at a dosage of about 3.0 mg/kg based on the weight of the subject.

7 . The method of claim 1 , wherein the CD19-ADC is administered once every 6 weeks.

8 . The method of claim 1 , wherein the CD19-ADC is administered on day 1 of the 6-week cycle.

9 . The method of claim 1 , wherein rituximab is administered at a dosage between about 350 mg/m 2 to about 400 mg/m 2 based on the body surface area of the subject.

10 . The method of claim 9 , wherein rituximab is administered at a dosage of about 375 mg/m 2 based on the body surface area of the subject.

11 . The method of claim 9 , wherein rituximab is administered once every 3 weeks.

12 . (canceled)

13 . The method of claim 1 , wherein cyclophosphamide is administered at a dosage between about 700 mg/m 2 to about 800 mg/m 2 based on the body surface area of the subject.

14 . The method of claim 13 , wherein cyclophosphamide is administered at a dosage of about 750 mg/m 2 based on the body surface area of the subject.

15 . The method of claim 13 , wherein cyclophosphamide is administered once every 3 weeks.

16 . (canceled)

17 . The method of claim 1 , wherein doxorubicin is administered at a dosage between about 40 mg/m 2 to about 60 mg/m 2 based on the body surface area of the subject.

18 . The method of claim 17 , wherein doxorubicin is administered at a dosage of about 50 mg/m 2 based on the body surface area of the subject.

19 . The method of claim 17 , wherein doxorubicin is administered once every 3 weeks.

20 . (canceled)

21 . The method of claim 1 , wherein prednisone is administered at a dosage between about 80 mg to about 100 mg.

22 . The method of claim 21 , wherein prednisone is administered at a dosage of about 100 mg.

23 . The method of claim 20 , wherein prednisone is administered multiple times during a 3-week cycle.

24 . (canceled)

Assignments (1)
CHANGE OF NAME Recorded Oct 21, 2020
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 054174/0595 →